Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

A syndecan-based genetic approach to coat the surface of small extracellular vesicles with Nanobodies

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Contributors:
      Centre de Recherche en Cancérologie de Marseille (CRCM); Aix Marseille Université (AMU)-Institut Paoli-Calmettes (IPC); Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS); Vrije Universiteit Brussel Bruxelles (VUB); Catholic University of Leuven = Katholieke Universiteit Leuven (KU Leuven); Institut Paoli-Calmettes (IPC); Fédération nationale des Centres de lutte contre le Cancer (FNCLCC); Centre National de la Recherche Scientifique (CNRS); Institut National de la Santé et de la Recherche Médicale (INSERM); Aix Marseille Université (AMU)
    • Publication Information:
      CCSD
    • Publication Date:
      2026
    • Collection:
      Aix-Marseille Université: HAL
    • Abstract:
      Small extracellular vesicles (sEVs) are promising vehicles for targeted therapeutic delivery, but strategies for their surface functionalization remain limited. Here, we present a reliable and simple genetic approach that enables customized modification of sEV surfaces and supports enhanced sEV uptake by recipient cells. This strategy is based on the fusion of targeting moieties to the C-terminal fragment of syndecan-1 (SDC1-CTF), a peptide naturally enriched in sEVs. Combining various analytical approaches including single-vesicle analysis, we establish that this strategy enables decoration of up to 20% of secreted sEVs with nanobodies (Nbs). In quantitative bioluminescence assays, using concentrated conditioned media, we demonstrate that sEV-coating with anti-EGFR Nb supports enhanced sEV uptake by EGFR-expressing cells. This new strategy thus offers a robust and modular solution for endowing sEV surfaces with defined targeting properties to support further sEV-based therapeutic applications.
    • Relation:
      BIORXIV: 2026.01.29.702589
    • Accession Number:
      10.64898/2026.01.29.702589
    • Online Access:
      https://hal.science/hal-05526712
      https://hal.science/hal-05526712v1/document
      https://hal.science/hal-05526712v1/file/2026.01.29.702589v1.full.pdf
      https://doi.org/10.64898/2026.01.29.702589
    • Rights:
      https://creativecommons.org/licenses/by/4.0/ ; info:eu-repo/semantics/OpenAccess
    • Accession Number:
      edsbas.C07AB39